244 related articles for article (PubMed ID: 12942110)
61. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
62. [Intravenous continuous infusion of fluorouracil for treatment of metastatic colorectal cancer].
Hosokawa A
Nihon Rinsho; 2003 Sep; 61 Suppl 7():352-5. PubMed ID: 14574911
[No Abstract] [Full Text] [Related]
63. Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer.
Miyamoto S; Boku N; Ohtsu A; Yoshida S; Ochiai A; Okabe H; Fukushima M
Int J Oncol; 2000 Oct; 17(4):653-8. PubMed ID: 10995874
[TBL] [Abstract][Full Text] [Related]
64. Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer.
Tamura T; Kuwahara A; Kadoyama K; Yamamori M; Nishiguchi K; Inokuma T; Takemoto Y; Chayahara N; Okuno T; Miki I; Fujishima Y; Sakaeda T
Int J Med Sci; 2011; 8(5):406-12. PubMed ID: 21750645
[TBL] [Abstract][Full Text] [Related]
65. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group.
Sugimachi K; Maehara Y; Horikoshi N; Shimada Y; Sakata Y; Mitachi Y; Taguchi T
Oncology; 1999 Oct; 57(3):202-10. PubMed ID: 10545788
[TBL] [Abstract][Full Text] [Related]
66. Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.
Hirose T; Fujita K; Nishimura K; Ishida H; Yamashita K; Sunakawa Y; Mizuno K; Miwa K; Nagashima F; Tanigawara Y; Adachi M; Sasaki Y
Oncol Rep; 2010 Aug; 24(2):529-36. PubMed ID: 20596643
[TBL] [Abstract][Full Text] [Related]
67. The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: a preliminary report.
Cai X; Fang JM; Xue P; Song WF; Hu J; Gu HL; Yang HY; Wang LW
Eur Rev Med Pharmacol Sci; 2014; 18(8):1247-58. PubMed ID: 24817302
[TBL] [Abstract][Full Text] [Related]
68. Measurement of plasma 5-fluorouracil by high-performance liquid chromatography with comparison of results to tissue drug levels observed using in vivo 19F magnetic resonance spectroscopy in patients on a protracted venous infusion with or without interferon-alpha.
Findlay MP; Raynaud F; Cunningham D; Iveson A; Collins DJ; Leach MO
Ann Oncol; 1996 Jan; 7(1):47-53. PubMed ID: 9081391
[TBL] [Abstract][Full Text] [Related]
69. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
[TBL] [Abstract][Full Text] [Related]
70. Evaluation of 5-FU plasma concentration by 13C breath test in patients treated with oral 5-FU analogs.
Higashida M; Matsumoto H; Kubota H; Murakami H; Kawabe Y; Nakashima H; Oka Y; Okumura H; Nakamura M; Hirai T
Anticancer Res; 2012 Dec; 32(12):5407-14. PubMed ID: 23225444
[TBL] [Abstract][Full Text] [Related]
71. Oral eniluracil/5-FU for advanced colon and breast carcinomas.
Benson AB
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):57-63; discussion 64. PubMed ID: 11219979
[TBL] [Abstract][Full Text] [Related]
72. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
Keith B; Guo XD; Zentko S; Harold N; Schuler B; Quinn M; Shapiro J; Grem JL
Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
[TBL] [Abstract][Full Text] [Related]
73. A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.
Etienne-Grimaldi MC; François E; Cardot JM; Renée N; Douillard JY; Gamelin E; Bennouna J; Château Y; Milano G
Clin Pharmacokinet; 2007; 46(11):953-63. PubMed ID: 17922560
[TBL] [Abstract][Full Text] [Related]
74. Correct fluorouracil (5-FU) half-life comparator for a 5-FU prodrug plus a dihydropyrimidine dehydrogenase inhibitor.
White RM
J Clin Oncol; 2001 Jun; 19(11):2970. PubMed ID: 11387375
[No Abstract] [Full Text] [Related]
75. The oral fluorouracil prodrugs.
Pazdur R; Hoff PM; Medgyesy D; Royce M; Brito R
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):48-51. PubMed ID: 9830626
[TBL] [Abstract][Full Text] [Related]
76. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion.
Harris BE; Song R; Soong SJ; Diasio RB
Cancer Res; 1990 Jan; 50(1):197-201. PubMed ID: 2293556
[TBL] [Abstract][Full Text] [Related]
77. Oral fluoropyrimidines in the treatment of colorectal cancer.
Meropol NJ
Eur J Cancer; 1998 Sep; 34(10):1509-13. PubMed ID: 9893621
[TBL] [Abstract][Full Text] [Related]
78. Drug delivery of oral anti-cancer fluoropyrimidine agents.
Miura K; Shima H; Takebe N; Rhie J; Satoh K; Kakugawa Y; Satoh M; Kinouchi M; Yamamoto K; Hasegawa Y; Kawai M; Kanazawa K; Fujiya T; Unno M; Katakura R
Expert Opin Drug Deliv; 2017 Dec; 14(12):1355-1366. PubMed ID: 28379040
[TBL] [Abstract][Full Text] [Related]
79. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: a novel class of oral antineoplastic agents.
Hoff PM; Pazdur R
Semin Oncol; 1999 Dec; 26(6 Suppl 18):52-6. PubMed ID: 10892578
[TBL] [Abstract][Full Text] [Related]
80. Just when you thought the fluorouracil debate was over: S-1 and gastric cancer.
Ilson D
J Clin Oncol; 2005 Oct; 23(28):6826-8. PubMed ID: 16145059
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
